Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials

Lipids in Health and Disease

Bin Tang¹  Xiaojun Tu¹  Chengfeng Qiu¹  Shilong Jiang²  Xiang Zhao³  Ziwei Deng⁴  Lang She⁴  Zhihua Shi⁴  Liming Tan⁵ 

[1]Departement of Evidence-base Medcine and Clinical center, The First People’s Hospital of Huaihua of University of South China

[2]Department of Clinical Pharmaccology, Xiangya Hospital Central South University

[3]Department of General Practice, The First People’s Hospital of Huaihua of University of South China

[4]Department of Pharmacology, The First People’s Hospital of Huaihua of University of South China

[5]Department of Pharmacology, The Second People’s Hospital of Huaihua City

关键词: Baricitinib;    Rheumatoid arthritis;    Low-density lipoprotein cholesterol;    High-density lipoprotein cholesterol;    Cardiovascular risk;   

DOI  :  10.1186/s12944-019-0994-7

来源: DOAJ

【 摘 要 】

Abstract Background Baricitinib, an oral-administrated selective inhibitor of the JAK1 and JAK2, is recently approved for rheumatoid arthritis (RA) treatment. With the aim to provide some insights on the clinical safety, the current study mainly focused on the effect of baricitinib on low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels and cardiovascular risk. Methods The net change scores [least squares mean (LSM) and mean change] of LDL-C and HDL-C levels from baseline with the comparison of baricitinib versus placebo were pooled, respectively. Risk rations (RR) of major cardiovascular events (MACEs) and differences of cardiovascular risk scores at the end of treatment across groups were compared. Results Six trials with randomized 3552 patients were finally included in summary analysis. Results showed that baricitinib significantly increased LDL-C levels, the net mean change was 13.15 mg/dl with 95% CI 8.89~17.42 (I2 = 0) and the net LSM was 11.94 mg/dl with 95% CI 7.52~16.37 (I2 = 84%). HDL-C also increased obviously with the net LSM change was 7.19 mg/dl (95% CI, 6.05~8.33, I2 = 47%) and net mean change was 5.40 mg/dl (95% CI, 3.07~7.74, I2 = 10%). Subgroup and meta-regression analysis demonstrated baricitinib induced LDL-C and HDL-C increases in a dose-response manner. However, both the pooled RRs of MACEs and differences of cardiovascular risk scores were not statistically significant across groups. Conclusion This study confirmed that baricitinib induced a stable dose-response increase in LDL-C and HDL-C levels. Since the causality association between altered lipids and cardiovascular risk was not identified yet, this issue cannot be completely dismissed. Future research is needed to fully dissect the implications of these lipid changes.

【 授权许可】

Unknown